阿法替尼与非小细胞肺癌T790M基因的研究进展

Progress of t790min non small cell lung cancer

第一代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)广泛运用于EGFR突变的晚期非小细胞肺癌(NSCLC)的治疗,使多数患者获得超过两年的生存期,但是获得性耐药的产生,限制了其继续使用的临床疗效,超过50%的耐药患者为20号外显子管家基因EGFR发生T790M突变。阿法替尼是第二代不可逆抗人表皮生长因子受体(HER)制剂,近年来有学者发现其能抑制T790M突变的肿瘤细胞生长,对使用第一代EGFR-TKI耐药的NSCLC患者仍然有一定疗效,但是其作用机制仍不清楚。本文就阿法替尼对T790 M基因突变所致耐药的晚期非小细胞肺癌研究进展进行综述,为T790M突变型NSCLC的研究及治疗提供新的参考。

The first epidermal growth factor receptor tyrosine kinase inhibitor（EGFR-TKI）is widely used in EGFR mutation of advanced non-small cell lung cancer（NSCLC）treatment,the majority of patients received more than two years of survival,but acquired resistance has limited its use to clinical curative effect,more than 50% of exon 20 for drug resistant patients exon housekeeping gene EGFR T790 M mutation.Afatinib is the second generation of irreversible anti human epidermal growth factor receptor（HER）in recent years,scholars have found that the preparation can inhibit the growth of T790 M mutations in tumor cells,still have a certain effect on the use of a generation of EGFR-TKI resistant NSCLC patients,but the mechanism is still not clear.This review will review the progress in the study of drug-resistant advanced non-small cell lung cancer（NSCLC）caused by mutations in T790 M gene and provide a new reference for the study and treatment of T790 M mutant NSCLC.